Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia

• Status: Recruiting
• Trial end date: 2021-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Thalidomide is known to have hypnosedative, immuno-modulatory and anti-angiogenic effects. The drug is widely used in several neoplastic disorders (e.g. multiple myeloma and malignant melanoma), inflammatory conditions (e.g. Crohn's disease) and skin disorders (e.g. leprosy). Thalidomide has been successfully used in adult thalassemia patients. The current study explores its role in younger thalassemia patients.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Blood Diseases Clinic
• Treatments: Thalidomide

Criteria

Inclusion Criteria:

• Transfusion dependent thalassemia patients

Exclusion Criteria:

• Those with active systemic comorbidity, with past personal or family history of thrombophilia or history of splenectomy in the past 6 months